Related Experiment Video
Updated: Aug 19, 2026

Biochemical Measurement of Neonatal Hypoxia
Published on: August 24, 2011
Effect of oral metrizamide on hematocrit and serum osmolality in the neonate
Abstract:
Sixteen newborns and young infants, weighing between 800 and 5200 grams, received orally administered metrizamide for evaluation of suspected gastrointestinal pathology. Images were judged good to excellent in 14 cases. No effect of metrizamide on hematocrit and serum osmolality was noted. Metrizamide appears to be a relatively safe and effective agent for examination of the neonatal gastrointestinal tract.
Insights
Oral metrizamide is a safe and effective agent for evaluating gastrointestinal issues in newborns and infants. This study found good to excellent imaging results with no adverse effects on key health indicators.
Area of Science:
- Pediatric Radiology
- Gastroenterology
- Medical Imaging
Background:
- Gastrointestinal pathology in newborns requires accurate diagnostic methods.
- Evaluating the safety and efficacy of contrast agents in infants is crucial.
Purpose of the Study:
- To assess the safety and effectiveness of oral metrizamide for neonatal gastrointestinal examinations.
- To determine the diagnostic quality of images obtained using metrizamide in infants.
Main Methods:
- Sixteen newborns and young infants (800-5200g) received oral metrizamide.
- Radiographic images were evaluated for diagnostic quality.
- Hematocrit and serum osmolality were monitored for adverse effects.
Main Results:
- Oral metrizamide was administered to 16 infants for suspected gastrointestinal pathology.
- 14 out of 16 cases (87.5%) yielded good to excellent image quality.
- No significant changes in hematocrit or serum osmolality were observed post-administration.
Conclusions:
- Metrizamide is a safe and effective oral contrast agent for neonatal gastrointestinal imaging.
- The agent provides high-quality images, aiding in the diagnosis of infant gastrointestinal conditions.
Related Concept Videos
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
IV Infusion to Oral Dosing: Conversion Methods
Drug Dosing: Infants and Children
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmacokinetics in Pediatric Patients: Drug Distribution
Oral Hypoglycemic Agents: Biguanides and Glitazones

